Now I have a clear picture of the calibration landscape. Let me write the final review.

**Round 1 bracket**: Based on calibration search, the paper sits somewhere between the weak anchors (scores 2-3) and middle anchors (scores 4-6). The paper has genuine contributions but also a clear structural flaw in the main comparison. Initial bracket: **3.5 - 5.5**.

**Round 2 narrowing**: After reading full reviews of anchors at 4.00 (jgVqCCg5XX - scaling effects), 4.25 (MEztAJjcYZ - clinical note summarization), 4.20 (YAMlVKRLnc - ClinicalLab), and 4.33 (gYcft1HIaU - clinical knowledge), the paper under review is closest to the 4.0-4.3 range. The experimental design confound is more serious than issues in those papers, but the collapse analysis finding is genuinely novel and the zero-shot comparison is fair. Final score: **4.0**.

---

## Summary

This paper evaluates small LMs (≤3B parameters) against large, medically adapted LMs (7-8B) on clinical text summarization (MeQSum) and small VLMs against large VLMs on radiology report generation (MIMIC-CXR). The authors find that after LoRA fine-tuning, certain 1B-scale LMs (Gemma-3-1B, LLaMA-3.2-1B) can achieve higher scores on BLEU, ROUGE-L, BERTScore, and MEDCON than large medical LMs used in zero-shot. They introduce a "Collapse Analysis" framework showing that below ~1B parameters, hallucination rates spike sharply. For radiology report generation, small VLMs lag behind large VLMs even after fine-tuning.

## Strengths

- **Identification of a sharp safety-collapse threshold around 1B parameters (Table 3).** The paper demonstrates a non-uniform degradation pattern: prompt robustness erodes first, and hallucination rates jump from 2-3% at 1.7B to 18-75% at sub-billion scales (SmolLM2-360M, Gemma-3-270M). This is a genuinely useful finding for practitioners deciding on a minimum viable model size for clinical deployment.

- **The zero-shot comparison (Table 2) provides a fair and informative baseline.** Both small and large models are evaluated under identical conditions. SmolLM2-1.7B achieves a BERTScore of 0.9007 (highest among all models) and MEDCON of 0.271 (competitive with BioMistral-7B's 0.295 and OpenBioLLM-8B's 0.336), showing that a 1.7B general-purpose model can rival 7-8B domain-adapted models on semantic and concept-level metrics without any fine-tuning. This is a real, non-confounded result.

- **The radiology report generation experiments (Table 4) use a more honest setup and yield a credible negative result.** Small VLMs (Florence 2, Qwen2.5-VL) are fine-tuned on 10K MIMIC-CXR pairs and still fall short of large VLMs (Med-Flamingo, LLaVA-Med) on all metrics. Figure 4 provides a concrete qualitative illustration. This finding advances the community's understanding of where small models can and cannot substitute for larger ones.

## Weaknesses

### Fatal
None.

### Major

1. **The headline comparison (LoRA fine-tuned small LMs vs. ICL-only large LMs) confounds model size with adaptation method.** The paper's central claim — that after LoRA, "all small LMs outperformed large LMs across every metric" — is a comparison between small models fine-tuned on the target dataset (MeQSum) and large models evaluated only in zero-shot (ICL). No large LM receives the same LoRA treatment. This is not a test of whether size is the barrier; it is a test of whether fine-tuning compensates for small size. The practical scenario (fine-tune a small model vs. use a large one off-the-shelf) is worth studying, but the paper frames the experiment as a pure size comparison, and the title asks "Is Model Size a Barrier to Quality?" — the experiment cannot answer this question.

2. **The claim "all small LMs outperformed large LMs across every metric" is factually inaccurate for SmolLM2-1.7B.** From Figure 3: SmolLM2-1.7B LoRA achieves ROUGE-L ~30.5% vs. OpenBioLLM-8B ICL ~31.5% (lower), and BERTScore ~86% vs. OpenBioLLM-8B ICL ~90% (lower). The paper's own Results section (Section 4) partially qualifies this ("SmollM2's gains were less pronounced"), but the blanket statement "all small LMs outperformed" appears in both the Results section and the Discussion and should be corrected.

3. **The Collapse Analysis metrics (Table 3) are presented without any operational definition.** The paper reports Task Adherence, Hallucination Rate, Clinical Concept Recall, Prompt Robustness, and a Readiness Score to two decimal places, but never states how any of these are computed. There is no rubric, no annotation protocol, no inter-rater reliability, and no description of an automated measurement procedure. A reader cannot tell whether a reported 18.3% hallucination rate for SmolLM2-360M is clinically meaningful or an artifact of the (unseen) measurement process. This is the paper's most novel contribution, yet it is presented as a black box, making it unverifiable and irreproducible.

### Minor

4. **No variance or confidence intervals.** All metrics (BLEU, ROUGE-L, BERTScore, MEDCON, and all collapse dimensions) are reported as point estimates without standard deviations, bootstrap estimates, or significance tests. Given that many of the reported differences between models are small (e.g., BLEU 0.069 vs. 0.046 in Table 2), it is impossible to judge whether any of the reported orderings are statistically meaningful.

5. **The domain-adaptation confound in the zero-shot comparison is not acknowledged.** The "large LMs" (BioMistral-7B, Med-LLaMA-8B, OpenBioLLM-8B) are all domain-adapted on medical corpora; the "small LMs" (LLaMA-3.2-1B, Gemma-3-1B, SmolLM2-1.7B) are general-purpose. Table 2 thus measures the combined effect of size + domain adaptation, not size alone. This does not invalidate the results but limits what can be concluded from Table 2 specifically.

6. **Fine-tuning hyperparameters are largely unreported.** The paper does not specify LoRA rank/alpha, learning rate, number of epochs, batch size, or the size of the training set. The phrase "MeQ-Small corpus" appears once (Section 4) but is not defined — is this a subset of MeQSum? How many examples? The training objective equation (cross-entropy loss) is given but none of the actual training details.

### Trivial
None.

## Nice-to-Haves

- A cost or latency comparison (inference time, GPU memory, FLOPs) would strengthen the practical motivation.
- A human evaluation or validation of the collapse metrics against clinical judgment would substantially strengthen the safety claims.
- Reporting results on more of the MIMIC-CXR data (the paper uses 10K pairs out of 200K+ available) would improve the radiology experiments.

## Removed Points
- The harsh critic's point about "the zero-shot comparison confounds model size with domain adaptation" — this is partially valid (the paper should acknowledge it) but Table 2's zero-shot comparison is still informative. Kept as Minor #5.
- Critic's point about decoding strategy (top-k=3, top-p=0.9, T=0.3) being unusual — this is a design choice, not a flaw, and the paper states it explicitly. Removed as a style nitpick.
- Critic's point about "no human evaluation of clinical acceptability" — this is a nice-to-have, not a required methodology for every clinical NLP paper. Moved to Nice-to-Haves.
- Critic's point about "the collapse analysis is performed on only two model families" — this is reasonable scope for a conference paper. Removed.
- Critic's point about "Florence 2 and Qwen 2.5-VL using different prompts" — this is a valid concern but is a standard practice of using each model's recommended template. Not a weakness that threatens the paper.
- Critic's point about "no inference cost or latency comparison" — moved to Nice-to-Haves.

## Novel Insights
The harsh critic correctly identifies that the paper's central finding is confounded by fine-tuning status, but misses that the paper's most robust contribution may be the zero-shot results (Table 2) and the collapse threshold. The strength finder correctly highlights the collapse analysis as the most interesting finding, but overstates the paper's claims about fine-tuned small models surpassing large ones. The real novelty is in the non-uniform degradation profile — prompt robustness degrades before hallucination spikes — which is a finer-grained observation than a single overall score would capture. The radiology finding that small VLMs cannot close the gap even with fine-tuning is also a genuinely useful negative result.

## Suggestions
1. Equalize the comparison: apply LoRA to the large LMs as well. Even a single adapter run on BioMistral-7B or OpenBioLLM-8B would determine whether fine-tuned large models further outperform the small LoRA-tuned models.
2. Define and validate the collapse metrics. Even a brief operational definition (e.g., "hallucination = generation of a clinical finding not present in the reference, measured by UMLS concept mismatch") would make Table 3 interpretable. A small human annotation study on a subset would be ideal.
3. Add confidence intervals or standard deviations to all metric tables.
4. Correct the overstated claim "all small LMs outperformed large LMs across every metric" to reflect that SmolLM2-1.7B does not uniformly outperform the large models.
5. Report fine-tuning hyperparameters and clarify what "MeQ-Small corpus" refers to.

## Score and Decision

**Round 1 bracket**: [3.5, 5.5] — based on calibration search comparing against weak-anchor papers (avg 2-3), middle-anchor papers (avg 4-6), and strong-anchor papers (avg 7.5+).

**Round 2 narrowing**: Compared against five fully-read anchor papers (MEztAJjcYZ at 4.25, jgVqCCg5XX at 4.00, YAMlVKRLnc at 4.20, gYcft1HIaU at 4.33, ztpy1gsUpT at 6.00). The paper under review is most comparable to the 4.0-4.3 anchors: it has interesting findings and a practical question, but the main experimental comparison is confounded (more severely than the issues in those anchor papers), the collapse metrics are undefined, and central claims are overstated. It does not reach the 6.0 level of ztpy1gsUpT, which had a clean experimental design and clear contributions with no comparable confound.

**Final score**: 4.0

MY FINAL SCORE: <score>4.0</score>
MY FINAL DECISION: <decision>Reject</decision>